PR99587

CHENGDU, China, Feb. 20, 2023 /PRNewswire=KYODO JBN/ --

Recently, with the support of the National Key R&D Program of China, following

the clinical trial approval for Recombinant Variant COVID-19 Vaccine (Sf9 cell)

approved by NMPA, WestVac Biopharma (Guangzhou) Co., Ltd. (hereinafter referred

to as "WestVac Biopharma (Guangzhou)")  has made significant progress on the

development of the trivalent recombinant protein COVID-19 vaccine against the

latest prevalent subvariants including XBB.1.5 and BA.5, which is one of the

first trivalent recombinant protein vaccines targeting XBB.1.5 worldwide.

Taking advantage of the rapid response of the internationally advanced insect

cell expression platform in recombinant protein vaccine production, WestVac

Biopharma (Guangzhou) has constructed the vector within one month, and produced

the trivalent recombinant protein vaccine of high purity and quality for human

use. It is an entirely synthetic vaccine. The subunit vaccine antigen is

precisely designed based on the structure of the targeting S-RBD and HR protein

of XBB.1.5 and BA.5 subvariants, and can self-assemble into stable trimeric

protein particles. Study revealed that the vaccine induced high titers of

neutralizing antibodies against Omicron XBB.1.5, BQ.1, BF.7, BA.5, BA.2.75 and

other subvariants, suggesting that it is a broad-spectrum COVID-19 vaccine

against multiple prevalent subvariants at home and abroad such as XBB.1.5,

BQ.1, BF.7 and BA.5. At present, WestVac Biopharma is proactively engaged with

the national authorities, and striving to meet the national approval

requirements as soon as possible for the trivalent recombinant protein

vaccine.The mission is to use WestVac BioPharma's power to aid in the fight

against new variants of novel coronavirus!

WestVac Biopharma (Guangzhou) is a wholly-owned subsidiary of WestVac Biopharma

Co., Ltd. located in the Innovative Vaccine Production Base in the Knowledge

City of Guangzhou Economic Development Zone. With the production lines of a

combined 5000L to be constructed soon for insect cell recombinant protein

vaccine and nasal spray vaccine, it will have an annual production capacity of

500 million doses of vaccines.

WestVac Biopharma Co., Ltd., the parent company, is an innovative

biopharmaceutical company integrating vaccine R&D, production and sales. From

2021 to 2022, WestVac Biopharma was selected successfully on the list of

unicorn companies for two consecutive years. Coviccine® --Recombinant COVID-19

Vaccine (Sf9 cell) developed by WestVac Biopharma has shown satisfactory safety

and immunogenicity in clinical trial with 70.95% protective efficacy against

Omicron subvariants, which is one of the most effective vaccines in preventing

symptomatic COVID-19 cases with Omicron subvariants in the world. In December

2022, Coviccine® has been approved by the national authority for emergency use

and already been in the bidding process and supplied for vaccination in

multiple provinces. In the meantime, Recombinant Variant COVID-19 vaccine (Sf9

cell) developed by WestVac Biopharma has recently received the Approval for

Clinical Trial by NMPA, the phase I/II clinical trials will soon begin.

SOURCE: WestVac BioPharma Co., Ltd.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=438015

   Caption: WestVac BioPharma Co., Ltd.